Child's heart transforming into a flower, symbolizing Tetralogy of Fallot treatment.

From Blue Baby to Thriving Adult: A Tetralogy of Fallot Success Story

Samir D’Costa monogram
Samir D’Costa in Health & Wellness November 2026 • 5 min read.

"Explore the remarkable journey of a patient with Tetralogy of Fallot, showcasing the evolution of cardiac surgery and the complexities of long-term care for congenital heart disease."


Tetralogy of Fallot (ToF), once known as 'La Maladie Bleue' or the blue disease, is a congenital heart defect involving a combination of four heart abnormalities. These include a large ventricular septal defect (VSD), an overriding aorta, pulmonary stenosis, and right ventricular hypertrophy. This complex condition reduces the amount of oxygenated blood reaching the body, leading to cyanosis (a bluish tint to the skin) and other serious health issues.

Historically, ToF was a significant cause of infant mortality. However, advancements in surgical techniques have dramatically improved the prognosis for individuals born with this condition. The first palliative surgery for ToF was performed in 1945, followed by the first complete correction in 1954. These milestones marked the beginning of a new era in the treatment of congenital heart disease.

This article presents a case study of a 65-year-old woman who underwent surgical treatment for ToF, illustrating the complexities of managing this condition over the long term and the significant impact of medical advancements on the lives of patients with congenital heart defects.

AI Search Multiple angles on this topic

Modern ToF Management

Tetralogy of Fallot consists of a mal-aligned ventricular septal defect, aortic override, pulmonary stenosis, and resultant right ventricular hypertrophy, a combination formally named by Etienne-Louis Fallot in 1888. Early treatment of cyanotic children helped establish modern congenital heart surgery through procedures such as the Blalock-Thomas-Taussig shunt. Contemporary care may involve pediatric intensive care teams before, during, and after surgery, while the American Association for Thoracic Surgery notes that important management questions remain controversial and that newer strategies are sometimes supported by limited data.

Three Centuries of Discovery

The historical development of tetralogy of Fallot forms part of a broader evolution in cardiology, cardiac surgery, and understanding of the developing heart. A historical review traces descriptions of the defect back to Steno of Denmark in 1673 and follows the development of new tools and concepts. Modern anatomical definitions describe ToF through anterosuperior deviation of the conal or outlet septum, pulmonary outflow narrowing or atresia, a malalignment-type ventricular septal defect, and aorta connected to both ventricles.

A Lifelong Journey with Tetralogy of Fallot: From Palliative Care to Complete Correction

Child's heart transforming into a flower, symbolizing Tetralogy of Fallot treatment.

Our patient's journey began in toddlerhood, marked by noticeable cyanosis and the characteristic 'squatting' position after physical exertion. At six years old, she underwent a palliative Potts anastomosis, a surgical procedure designed to improve blood flow to the lungs by creating a connection between the left pulmonary artery and the descending aorta. This intervention helped to alleviate her symptoms but wasn't a permanent solution.

As she entered her third decade, a heart catheterization revealed the presence of malignant pulmonary hypertension, a serious complication that increases the risk of further cardiac issues. In May 1987, she was advised to have a full corrective procedure in Houston, Texas, USA. The catheterization revealed a hyperkinetic state at the level of L-Rventricle at about 53mmHg (gradient at the level of aorta and pulmonary artery). A repeat catheterization in November 1987 confirmed the dominant left-to-right shunt, without fixation of pulmonary hypertension. At the time saturation in right ventricle was 61%, while saturation in pulmonary artery was 83%. The function of Potts shunt was still confirmed.

  • 1958 (Age 6): Potts anastomosis performed as palliative care.
  • 1987: Catheterization reveals malignant pulmonary hypertension.
  • Later: Complete correction surgery in Houston, Texas.
AI Search Multiple angles on this topic

Biomarkers and Developmental Biology

Recent research includes a study of NT-proBNP and hs-CRP as possible biomarkers for identifying and stratifying repaired TOF patients at increased risk of right-ventricular systolic dysfunction. That study included 32 adults with a mean age of 27.44 ± 6.22 years who underwent surgical correction during infancy. Separate mouse research examined interactive regulation between histone H3K9ac acetylation and H3K9me3 methylation during cardiomyogenesis, using 24 Kunming mice across embryonic and postnatal developmental stages.

The Cost of Non-Treatment

The cited clinical review presents untreated tetralogy of Fallot as carrying a severe long-term survival disadvantage. It reports that 11% of patients would not have experienced 20 years, 6% would not have experienced 30 years, and 3% would not have experienced 40 years without surgical treatment. These figures frame non-treatment as a major historical limitation rather than a viable alternative to repair.

Different Diagnostic Contexts

The listed sources illustrate that diagnostic thresholds and methods depend on the condition being evaluated. In a study involving idiopathic pulmonary fibrosis and suspected pulmonary hypertension, right-heart catheterization was performed when echocardiography suggested a right-ventricular systolic pressure above 40 mm Hg. By contrast, the CDC describes tetralogy of Fallot as a congenital defect formed during pregnancy, and Pediatric Echocardiography identifies it as the most common cyanotic congenital heart disease, comprising approximately 3.5% of infants born with congenital heart disease and 8-10% of cyanotic cases.

The complete correction involved closing the ventricular septal defect and addressing the pulmonary stenosis through infundibulectomy and valvuloplasty. During the operation, surgeons also closed an atrial septal defect. Post-surgery, she was treated with amiodarone and digoxin to manage heart rhythm and function. The patient has been regularly monitored since the surgery. Over time, she developed left ventricular dysfunction, persistent pulmonary arterial hypertension, and rhythm disorders, including atrial fibrillation and right bundle branch block. Regular check-ups revealed moderate regurgitation on both control valves, as well as aneurysmatic dilatation of the main branch of the left pulmonary artery. Treatment included ACE inhibitors, beta-blockers, diuretics, antiarrhythmic drugs, and anticoagulants. Despite these challenges, the patient remains in relatively stable condition at 65 years old.

Looking Ahead: The Future of Tetralogy of Fallot Treatment

This case underscores the remarkable progress made in the treatment of Tetralogy of Fallot. From early palliative procedures to complete surgical corrections, advancements in cardiology and cardiac surgery have transformed the lives of individuals born with this complex heart defect. As medical science continues to evolve, the focus is shifting towards addressing long-term complications and standardizing diagnostic and therapeutic approaches to ensure the best possible outcomes for patients with congenital heart disease.

AI Search Multiple angles on this topic

Measuring Long-Term Success

Long-term outcome research treats tetralogy of Fallot as a surgically repairable form of cyanotic congenital heart disease. A multicenter JAMA Cardiology study evaluated long-term transplant-free survival after repair while adjusting for surgical era and patient characteristics. A 2025 Journal of the American Heart Association study used centralized adjudication by two expert adult congenital heart disease cardiologists, with additional electrophysiology expertise among one adjudicator, to assess primary outcome events.

Living Beyond Repair

More than 70 years after the first successful surgical repair was described, tetralogy of Fallot remains a challenging form of congenital heart disease. The cited review reports that patients born with ToF can be expected to live into adulthood, with 30-year survival exceeding 95%. It also emphasizes that residual cardiac lesions after repair are nearly ubiquitous, making lifelong attention to late outcomes an important frontier.

Survival With Ongoing Care

The long-term outlook for people with tetralogy of Fallot has improved substantially, but repair does not eliminate every cardiac issue. The cited review states that 30-year survival exceeds 95% for patients born with ToF. It also notes that residual cardiac lesions after repair are nearly ubiquitous, underscoring the continuing need for specialized follow-up as survivors reach adulthood.

From Diagnosis to Daily Life

Case-based accounts show how tetralogy of Fallot can appear in real-world care. Children's Hospital of Philadelphia describes ToF as four structural defects: a ventricular septal defect, overriding aorta, pulmonary stenosis, and right-ventricle hypertrophy. A separate case report describes a 2-year-old girl with cyanotic congenital heart disease due to ToF who presented to an emergency room on November 5, 2024, with bluish discoloration of the skin.

What this late-repair case adds to the picture

The report pairs a relatively stable condition in later life with ongoing cardiac abnormalities, showing that stability and residual disease can coexist in this case.[1] [2]

Where this late-correction report is weakest

  • The authors note that complete correction is unusual so late because the operation carries high risk.[1]

The 65-year-old patient at the center of the report

PopulationA 65-year-old female patient with Tetralogy of Fallot[2]
SettingHouston, Texas, USA[2]
Times cited4[2]

How this case differs from larger repair cohorts

Several separate repaired-patient cohorts report survival at successive follow-up points, providing population-level context rather than outcomes for the woman in this case.[2] [3] [4] [5]

What a follow-up would need to clarify

  • The report notes a left ventricular ejection fraction near 50% after medication changes, but the cited case facts do not connect that measure to later stability or specific residual findings.[1] [2]

Terms used in the case report

Complete surgical correction
Closing the ventricular septal defect and addressing obstruction of the right ventricular outflow tract and pulmonary artery.[2]

Sources

  1. Tetralogy of Fallot - Clinical Course and Treatment as a Mirror of Contemporary Cardiology/Cardiac Surgery Development in Correction of Congenital Heart Disease in the Adults (Europe PMC, 2018)
  2. Tetralogy of Fallot - Clinical Course and Treatment as a Mirror of Contemporary Cardiology/Cardiac Surgery Development in Correction of Congenital Heart Disease in the Adults (ScopeMed, 2018)
  3. Survival and Freedom From Reinterventions in Patients With Repaired Tetralogy of Fallot: Up to 42‐Year Follow‐Up of 917 Patients (pmc.ncbi.nlm.nih.gov)
  4. Long-term follow-up after transatrial–transpulmonary repair of tetralogy of Fallot: influence of timing on outcome (pmc.ncbi.nlm.nih.gov)
  5. Long-term outcomes of tetralogy of Fallot repair: A 30-year experience with 960 patients. (pubmed.ncbi.nlm.nih.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

This article is based on research published under:

DOI-LINK: 10.5455/medarh.2018.72.224-226, Alternate LINK

Title: Tetralogy Of Fallot - Clinical Course And Treatment As A Mirror Of Contemporary Cardiology/Cardiac Surgery Development In Correction Of Congenital Heart Disease In The Adults

Subject: General Medicine

Journal: Medical Archives

Publisher: ScopeMed

Authors: Edin Begic, Zijo Begic, Dzenan Jahic, Enisa Hodzic

Published: 2018-01-01

Everything You Need To Know

1

What exactly is Tetralogy of Fallot?

Tetralogy of Fallot (ToF) is a congenital heart defect, meaning it's present at birth. It involves four specific abnormalities: a large ventricular septal defect (VSD), an overriding aorta, pulmonary stenosis, and right ventricular hypertrophy. These defects affect the flow of blood through the heart and to the body, reducing oxygen levels. This leads to cyanosis, a bluish discoloration of the skin, and can cause serious health problems if left untreated. In this context, understanding the components of ToF and the related terminology is crucial for comprehending the patient's condition and the interventions she underwent.

2

What is a Potts anastomosis and why is it done?

The Potts anastomosis is a palliative surgical procedure. It involves creating a connection between the left pulmonary artery and the descending aorta. The goal of this intervention is to improve blood flow to the lungs. In the case study, this procedure was performed when the patient was six years old to alleviate the symptoms associated with Tetralogy of Fallot (ToF). It's considered palliative because it doesn't fully correct the underlying heart defects; instead, it aims to improve the patient's quality of life until a complete correction can be performed. The significance of the Potts anastomosis lies in the fact that it provided some relief.

3

What does 'complete correction' for Tetralogy of Fallot mean?

Complete correction for Tetralogy of Fallot (ToF) involves addressing all four components of the defect. The ventricular septal defect is closed, the pulmonary stenosis is relieved through procedures like infundibulectomy and valvuloplasty, and any other associated defects, such as an atrial septal defect, are also repaired. In this case, it was performed in Houston, Texas. The significance of complete correction is that it aims to restore normal heart function. Although complete correction is a major advancement, patients may still experience long-term complications. In this case, the patient was monitored regularly after the surgery and treated with medications to manage any complications that arose.

4

What is malignant pulmonary hypertension and why is it important?

Malignant pulmonary hypertension is a serious complication that can develop in patients with congenital heart defects like Tetralogy of Fallot (ToF). It refers to abnormally high blood pressure in the pulmonary arteries, which carry blood from the heart to the lungs. This condition can place a strain on the heart and increase the risk of heart failure and other cardiac issues. In the case presented, malignant pulmonary hypertension was discovered during a heart catheterization and influenced the treatment plan. The presence of this condition underscored the complexity of the patient's case and the necessity of managing it throughout her life.

5

What does this case study show about the long-term implications of Tetralogy of Fallot?

This case study highlights the advancements in treating Tetralogy of Fallot (ToF), from early palliative procedures to complete surgical corrections. While the patient's journey demonstrates significant progress in cardiology and cardiac surgery, it also underscores the importance of long-term monitoring and management. The patient has had to deal with a variety of complications. Treatment included medications to manage heart rhythm and function, address the left ventricular dysfunction, pulmonary arterial hypertension, and rhythm disorders. This approach reflects the evolving understanding of the condition and the need for ongoing care to improve the lives of individuals born with this complex heart defect.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.